Peptides DB
Research-centric peptide and protocol reference hub
The GuardianNovember 4, 2026Regulatory

Australia’s first GLP-1 weight-loss pill has been approved. How does it differ to injections and who will be eligible?

Reported by The Guardian. Read the original →

What the story says

Australia has approved its first GLP-1 weight-loss pill. The article discusses how this pill differs from existing injection forms and outlines the eligibility criteria for potential users.

Summarised by a model from The Guardian's headline and its own description of the story. We did not read the article, and this is not our reporting — the link above is.

On file here

Every number below is counted from this library's own approved studies — the ones with a page you can open and check. Counts move as papers are filed.

What the headline doesn't tell you

  • This story is about a class — GLP-1 and incretin therapies — rather than one compound. We track 14 compounds in it, holding 344 studies between them, 150 in humans.

Counted, not written: each line is a sentence filled in from the study counts above. None of it is a judgement about the story or the compound.